Diabetomics Inc., is engaged in the development of Point-of-Care tests for Diabetes and Maternal Health. Diabetomics developed saliva/oral fluid technology for monitoring diabetes (Glucema) and detection of autoantibodies for Type 1 diabetes (Insudex). These technologies were quickly brought into focus in developing CovAb™ SARS-CoV-2 total antibody test using oral fluid sample.
COVYDx, Inc. was organized in July 2020 as a wholly owned subsidiary of Diabetomics, Inc. to conduct COVID-19 related business operations.